Aprogen subsidiary Aptn capital increase
에이프로젠
007460
Signal Score
Historical Avg Return (5d)
+0.26%
Data Coverage
100%n=2414
Risk-adjusted indicator based on 2414 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEGATIVE
Key Numbers
- • New Shares: 3,500,000 Shares (Common Stock)
- • Issue Price per Share: 1,000 KRW
- • Total Funding: 3,500,000,000 KRW
- • Pre-issuance Total Shares: 19,658,914 Shares
- • Dilution Rate: 17.80%
AI Analysis Summary
Aprogen's subsidiary, Aptn Inc., announced an amendment to its paid-in capital increase via third-party allotment. The new shares, totaling 3,500,000 common shares, will be issued at 1,000 KRW per share, raising 3.5 billion KRW. The funds are designated for acquiring securities of other corporations, specifically GPCR Co., Ltd., for new drug R&D. The payment date has been moved to July 7, 2026, and the listing date to August 11, 2026. This issuance represents a 17.80% dilution for existing shareholders. While the funds are for R&D, the dilution and the use of funds for another entity's securities acquisition could be viewed negatively by investors.
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.